Abstract
Hepatocyte growth factor/scatter factor (HGF/SF) acts as a mitogen, motogen and morphogen as well as an important angiogenic factor. In cancer cells, HGF/SF acts mainly as an inducer of cell migration and invasion with multiple motility signals mediated by the HGF receptor, c-MET. An important component in this signalling chain is the Rho/ROCK pathway, with resultant changes in cytoskeletal arrangement leading to cell motility/migration. This article outlines knowledge of HGF/SF in relation to cancer cell motility from previous reviews and focuses on more recent studies on the effect of HGF/SF in relation to RhoC GTPase and ROCK in breast cancer cells.
Keywords: Cancer cell motility, Hepatocyte growth factor/scatter factor, Rho, ROCK, GTPase, c-Met, metastasis, actin cytoskeleton, EMT, ribozyme, amoeboid cell motility, Y27632, lamellipodia, cancer cell invasion, RhoC, stress fibres, motility signals, Ras, doxycycline, mitogen, breat cancer, MDA-MB-231, MCF-7, Rho/rac pathway
Current Signal Transduction Therapy
Title: HGF and RhoGTPases in Cancer Cell Motility
Volume: 6 Issue: 2
Author(s): Jane Lane, Tracey A. Martin and Wen G. Jiang
Affiliation:
Keywords: Cancer cell motility, Hepatocyte growth factor/scatter factor, Rho, ROCK, GTPase, c-Met, metastasis, actin cytoskeleton, EMT, ribozyme, amoeboid cell motility, Y27632, lamellipodia, cancer cell invasion, RhoC, stress fibres, motility signals, Ras, doxycycline, mitogen, breat cancer, MDA-MB-231, MCF-7, Rho/rac pathway
Abstract: Hepatocyte growth factor/scatter factor (HGF/SF) acts as a mitogen, motogen and morphogen as well as an important angiogenic factor. In cancer cells, HGF/SF acts mainly as an inducer of cell migration and invasion with multiple motility signals mediated by the HGF receptor, c-MET. An important component in this signalling chain is the Rho/ROCK pathway, with resultant changes in cytoskeletal arrangement leading to cell motility/migration. This article outlines knowledge of HGF/SF in relation to cancer cell motility from previous reviews and focuses on more recent studies on the effect of HGF/SF in relation to RhoC GTPase and ROCK in breast cancer cells.
Export Options
About this article
Cite this article as:
Lane Jane, A. Martin Tracey and G. Jiang Wen, HGF and RhoGTPases in Cancer Cell Motility, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795660052
DOI https://dx.doi.org/10.2174/157436211795660052 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD
Current Alzheimer Research Nano-Chitosan Particles in Anticancer Drug Delivery: An Up-to-Date Review
Mini-Reviews in Medicinal Chemistry The Prognostic and Clinicopathologic Characteristics of OCT4 and Lung Cancer: A Meta-Analysis
Current Molecular Medicine Vitamin D, Sunlight and Cancer Connection
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Anticancer Actions of Omega-3 Fatty Acids - Current State and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Expression of Angiogenesis-related Genes in a Group of Iranian Cases of Breast Cancer
Current Pharmacogenomics and Personalized Medicine The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy
Current Pharmaceutical Design Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa)
Current Molecular Medicine Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells (NF-κB) – a Friend, a Foe, or a Bystander - in the Neurodegenerative Cascade and Pathogenesis of Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics
Drug Metabolism Letters Adult Retinal Ganglion Cell Axon Regeneration and Re-innervation
Current Tissue Engineering (Discontinued) MicroRNA and Cancer: Tiny Molecules with Major Implications
Current Genomics Writers and Erasers of Histone Lysine methylation with Clinically Applied Modulators: Promising Target for Cancer Therapy
Current Pharmaceutical Design State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry Combination of Histone Deacetylase Inhibitor with Cu(II) 5,5-diethylbarbiturate Complex Induces Apoptosis in Breast Cancer Stem Cells: A Promising Novel Approach
Anti-Cancer Agents in Medicinal Chemistry DNA Repair Proteins as Molecular Targets for Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design